Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Blue h2o who wrote (3175)	6/30/1999 9:35:00 AM
From: Silver Knife	Read Replies (1) \| Respond to of 3702

Company Press Release Wednesday June 30, 7:30 am Eastern Time Techniclone's Cotara Trial Data To Be Presented At International Congress on Brain Tumor Research Phase I Abstract Among Select Few to be Presented at Annual Conference TUSTIN, Calif.--(BUSINESS WIRE)--June 30, 1999--Techniclone Corporation (NASDAQ: TCLN - news), a developer of leading-edge unique therapeutics for the advanced treatment of cancer, announced today that the results of its Phase I trial for Cotara (TM), an innovative new therapy for the treatment of various forms of solid tumor cancer, will be presented by Dr. Sunil Patel (Medical University of South Carolina), principal investigator for the trial, at the 13th Annual International Congress on Brain Tumor Research being held Oct. 3-5 in Sapporo, Japan. The abstract, one of only 200 accepted for presentation during the prestigious conference, outlines the results of the 12 patient malignant glioma (brain cancer) study recently conducted at the Medical University of South Carolina. Commented Larry Bymaster, CEO, ''We are delighted that the trial results for Cotara (TM) will be presented before a number of the world's most prominent brain cancer researchers, and are certain that this conference will further increase awareness among the medical community about Cotara (TM) and its potential for the treatment of this deadly disease. ''While our Phase I study was primarily designed to determine the safety of Cotara (TM) we were very encouraged by the results which demonstrated that Cotara (TM) not only had specific uptake in brain tumors but that it appeared to be safe and resulted in shrinkage/stabilization in 50% of the patients at the doses administered. With Cotara (TM) targeting dead or dying cells found only at the core of tumors, investigators were able to deliver directly to the cancer site doses of radiation which were approximately a three-fold increase over the dose that can be given safely by external beam radiation alone.'' ''Techniclone's presence at this prestigious conference in Japan not only brings exposure for Cotara (TM) to an international audience, but will provide us with a forum to discuss business opportunities for this therapy with a very diverse and important group of corporate partners,'' stated John Bonfiglio, Ph.D., Vice President Technology and Business Development. Cotara (TM) is currently in a Phase II clinical study involving 60 malignant glioma brain cancer patients who receive two doses administered nine weeks apart, with dosage for each patient to be individualized based on a unique algorithm developed by Techniclone during the Phase I investigation. Company Overview: Techniclone Corporation is a biopharmaceutical company focused on the development, commercialization and licensing of unique technologies for the treatment of cancer primarily based on its ''collateral targeting technologies.'' These technologies therapeutically target cell structure and cell types, rather than surface cancer cells, as a means to attack solid tumors, without causing damage to surrounding healthy tissue. In addition to Cotara (TM), the company has two other collateral targeting agents: Vasopermeation Enhancement Agents (VEA) and Vascular Targeting Agents (VTA), both of which are in pre-clinical stages of development. VEAs are monoclonal antibodies that increase tumor blood vessel permeation for enhanced uptake of chemotherapeutic agents versus normal tissues, while VTAs are agents that block the flow of oxygen/nutrients to a solid tumor's vascular network, causing clotting and necrosis. VTAs also can deliver a wide variety of therapeutic agents to a solid tumor, including therapeutic agents, biologic agents, toxins and radioisotopes. The company also has a direct tumor targeting agent called Oncolym (R) for the treatment of advanced non-Hodgkin's B-cell Lymphoma which was recently licensed to Schering AG, Germany, who is now responsible for all existing and future Oncolym (R) clinical trial programs as well as marketing. Additional information on the company and its products can be found at www.techniclone.com. Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the company's expectations as a result of risk factors discussed in Techniclone's reports on file with the U.S. Securities and Exchange Commission, including, but not limited to the company's report on Form 10Q for the quarter ended Jan. 31, 1999 and Form 10K for the year ended April 30, 1998. Contact: Investor Relations: DeMonte Associates, New York Cynthia DeMonte, 212/420-0088 or Media Relations: Rubenstein PR, New York Clint Cantwell, 212/843-8051